Sinaf S.A. 4
4 · REGENERX BIOPHARMACEUTICALS INC · Filed Oct 17, 2017
Insider Transaction Report
Form 4
Sinaf S.A.
10% Owner
Transactions
- Conversion
Common Stock
2017-10-13+1,671,296→ 11,382,703 total - Other
Common Stock Warrant (right to buy)
2017-10-13−266,667→ 0 totalExercise: $0.15From: 2013-04-19Exp: 2017-10-19→ Common Stock (266,667 underlying) - Other
Common Stock
2017-10-13+266,667→ 11,649,370 total - Conversion
Convertible Promissory Note (right to buy)
2017-10-13−1,671,296→ 0 totalExercise: $0.15From: 2012-10-19→ Common Stock (1,671,296 underlying)
Footnotes (2)
- [F1]On October 13, 2017, the reporting person converted a $200,000 convertible promissory note (the "Note"), purchased from the issuer in a private placement on October 19, 2012, and accrued interest of $50,694.44 into common stock. The Note and accrued interest were convertible into common stock at the option of the holder at any time prior to repayment of the Note at a conversion price of $0.15 per share. Interest accrued on the unpaid principal amount at a rate equal to 5% per annum.
- [F2]On October 13, 2017, the reporting person exercised a warrant issued by the issuer to the reporting person in consideration of the reporting person's purchase of the Note at an exercise price of $0.15 per share of common stock.